Literature DB >> 25838421

High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease.

Anandita P Agarwala1, Amrith Rodrigues1, Marjorie Risman1, Mary McCoy1, Kevin Trindade1, Liming Qu1, Marina Cuchel1, Jeffrey Billheimer1, Daniel J Rader2.   

Abstract

OBJECTIVE: Plasma levels of high-density lipoprotein cholesterol (HDL-C) are strongly inversely associated with coronary artery disease (CAD), and high HDL-C is generally associated with reduced risk of CAD. Extremely high HDL-C with CAD is an unusual phenotype, and we hypothesized that the HDL in such individuals may have an altered composition and reduced function when compared with controls with similarly high HDL-C and no CAD. APPROACH AND
RESULTS: Fifty-five subjects with very high HDL-C (mean, 86 mg/dL) and onset of CAD at the age of ≈ 60 years with no known risk factors for CAD (cases) were identified through systematic recruitment. A total of 120 control subjects without CAD, matched for race, sex, and HDL-C level (controls), were identified. In all subjects, HDL composition was analyzed and HDL cholesterol efflux capacity was assessed. HDL phospholipid composition was significantly lower in cases (92 ± 37 mg/dL) than in controls (109 ± 43 mg/dL; P=0.0095). HDL cholesterol efflux capacity was significantly lower in cases (1.96 ± 0.39) than in controls (2.11 ± 0.43; P=0.04).
CONCLUSIONS: In people with very high HDL-C, reduced HDL phospholipid content and cholesterol efflux capacity are associated with the paradoxical development of CAD.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  ABC transporters; coronary artery disease; high-density lipoprotein cholesterol

Mesh:

Substances:

Year:  2015        PMID: 25838421      PMCID: PMC4560933          DOI: 10.1161/ATVBAHA.115.305504

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

1.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

Review 2.  High-density lipoprotein function recent advances.

Authors:  Benjamin J Ansell; Karol E Watson; Alan M Fogelman; Mohamad Navab; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2005-10-19       Impact factor: 24.094

3.  The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.

Authors:  Esther M M Ooi; P Hugh R Barrett; Gerald F Watts
Journal:  Int J Cardiol       Date:  2013-07-29       Impact factor: 4.164

4.  HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum.

Authors:  N Fournier; J L Paul; V Atger; A Cogny; T Soni; M de la Llera-Moya; G Rothblat; N Moatti
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

5.  The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease.

Authors:  Christina Piperi; Christos Kalofoutis; Dimitra Papaevaggeliou; Aggeliki Papapanagiotou; John Lekakis; Anastasios Kalofoutis
Journal:  Clin Biochem       Date:  2004-05       Impact factor: 3.281

Review 6.  High-density lipoprotein cholesterol and coronary heart disease.

Authors:  Christine E Young; Richard H Karas; Jeffrey T Kuvin
Journal:  Cardiol Rev       Date:  2004 Mar-Apr       Impact factor: 2.644

7.  Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease.

Authors:  Nebil Attia; Amel Nakbi; Maha Smaoui; Raja Chaaba; Philippe Moulin; Sonia Hammami; Khaldoun Ben Hamda; Françoise Chanussot; Mohamed Hammami
Journal:  Tohoku J Exp Med       Date:  2007-10       Impact factor: 1.848

8.  Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.

Authors:  Tomohiko Shimizu; Shin-ichiro Miura; Hiroyuki Tanigawa; Takashi Kuwano; Bo Zhang; Yoshinari Uehara; Keijiro Saku
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-07       Impact factor: 8.311

9.  Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients.

Authors:  Maki Miyamoto-Sasaki; Tomoyuki Yasuda; Tomoko Monguchi; Hideto Nakajima; Kenta Mori; Ryuji Toh; Tatsuro Ishida; Ken-ichi Hirata
Journal:  J Atheroscler Thromb       Date:  2013-06-05       Impact factor: 4.928

10.  Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase.

Authors:  Baohai Shao; Chongren Tang; Abhishek Sinha; Philip S Mayer; George D Davenport; Nathan Brot; Michael N Oda; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Circ Res       Date:  2014-03-19       Impact factor: 17.367

View more
  31 in total

1.  Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease.

Authors:  Kenji Norimatsu; Takashi Kuwano; Shin-Ichiro Miura; Tomohiko Shimizu; Yuhei Shiga; Yasunori Suematsu; Yuiko Miyase; Sen Adachi; Ayumi Nakamura; Satoshi Imaizumi; Atsushi Iwata; Hiroaki Nishikawa; Yoshinari Uehara; Keijiro Saku
Journal:  Heart Vessels       Date:  2016-04-22       Impact factor: 2.037

Review 2.  Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women.

Authors:  Anna C O'Kelly; Erin D Michos; Chrisandra L Shufelt; Jane V Vermunt; Margo B Minissian; Odayme Quesada; Graeme N Smith; Janet W Rich-Edwards; Vesna D Garovic; Samar R El Khoudary; Michael C Honigberg
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

3.  Molecular Patterns of Extreme and Persistent Cholesterol Efflux Capacity.

Authors:  Ayea El-Ghazali; Sneha Deodhar; Suzanne Saldanha; Brooke Smyth; Mark Izbrand; Anamika Gangwar; Mandana Pahlavani; Anand Rohatgi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-08-26       Impact factor: 10.514

4.  Associations of Endogenous Hormones With HDL Novel Metrics Across the Menopause Transition: The SWAN HDL Study.

Authors:  Samar R El Khoudary; Alexis Nasr; Jeffrey Billheimer; Maria M Brooks; Dan McConnell; Sybil Crawford; Trevor J Orchard; Daniel J Rader; Karen A Matthews
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 6.134

5.  Associations of Abdominal and Cardiovascular Adipose Tissue Depots With HDL Metrics in Midlife Women: the SWAN Study.

Authors:  Alexis Nasr; Karen Matthews; Imke Janssen; Maria M Brooks; Emma Barinas-Mitchell; Trevor J Orchard; Jeffrey Billheimer; Norman C Wang; Dan McConnell; Daniel J Rader; Samar R El Khoudary
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

Review 6.  High-density lipoproteins, reverse cholesterol transport and atherogenesis.

Authors:  Henry J Pownall; Corina Rosales; Baiba K Gillard; Antonio M Gotto
Journal:  Nat Rev Cardiol       Date:  2021-04-08       Impact factor: 32.419

7.  HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition: SWAN-HDL Study.

Authors:  Samar R El Khoudary ( سمر رياض الخضري ); Xirun Chen (陈曦润); Alexis Nasr ( ألكسس نصر ); Jeff Billheimer; Maria Mori Brooks; Dan McConnell; Trevor J Orchard; Sybil L Crawford; Karen A Matthews; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

8.  Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.

Authors:  María E Fernández-Suárez; Joan C Escolà-Gil; Oscar Pastor; Alberto Dávalos; Francisco Blanco-Vaca; Miguel A Lasunción; Javier Martínez-Botas; Diego Gómez-Coronado
Journal:  Sci Rep       Date:  2016-09-07       Impact factor: 4.379

9.  Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.

Authors:  Dong Zhao; Long-Yan Yang; Xu-Hong Wang; Sha-Sha Yuan; Cai-Guo Yu; Zong-Wei Wang; Jia-Nan Lang; Ying-Mei Feng
Journal:  Cardiovasc Diabetol       Date:  2016-09-13       Impact factor: 9.951

10.  Impact of Endothelial Lipase on Cholesterol Efflux Capacity of Serum and High-density Lipoprotein.

Authors:  Irene Schilcher; Sabine Kern; Andelko Hrzenjak; Thomas O Eichmann; Tatjana Stojakovic; Hubert Scharnagl; Madalina Duta-Mare; Dagmar Kratky; Gunther Marsche; Saša Frank
Journal:  Sci Rep       Date:  2017-10-02       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.